Lyra Therapeutics (LYRA) Accumulated Expenses (2019 - 2025)
Quarterly Accumulated Expenses fell 24.87% to $3.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $3.3 million through Dec 2025, down 24.87% year-over-year, with the annual reading at $3.3 million for FY2025, 24.87% down from the prior year.
Lyra Therapeutics' Accumulated Expenses history spans 7 years, with the latest figure at $3.3 million for Q4 2025.
- Accumulated Expenses came in at $3.3 million for Q4 2025, up from $3.1 million in the prior quarter.
- In the past five years, Accumulated Expenses ranged from a high of $11.1 million in Q3 2023 to a low of $1.8 million in Q2 2021.
- The 5-year median for Accumulated Expenses is $4.3 million (2022), against an average of $5.1 million.
- Year-over-year, Accumulated Expenses surged 271.76% in 2022 and then crashed 77.66% in 2025.
- Lyra Therapeutics' Accumulated Expenses stood at $2.4 million in 2021, then soared by 271.76% to $9.0 million in 2022, then increased by 3.81% to $9.4 million in 2023, then tumbled by 53.63% to $4.3 million in 2024, then decreased by 24.87% to $3.3 million in 2025.
- Per Business Quant, the three most recent readings for LYRA's Accumulated Expenses are $3.3 million (Q4 2025), $3.1 million (Q3 2025), and $3.5 million (Q2 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,384,976.65 Bn | 1,384,976.64 Bn | - |
| 2 | Alterity Therapeutics | 777,208.84 Bn | 777,208.81 Bn | - |
| 3 | Legend Biotech | 2,801.00 Bn | 2,800.10 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,226.01 Bn | 2,225.95 Bn | - |
| 5 | Akari Therapeutics | 605.66 Bn | 605.66 Bn | - |
| 6 | Vertex Pharmaceuticals | 110.17 Bn | 102.92 Bn | 2.59 Bn |
| 7 | Regeneron Pharmaceuticals | 66.86 Bn | 58.11 Bn | 3.31 Bn |
| 8 | Evaxion A | 65.12 Bn | 65.10 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.94 Bn | 36.94 Bn | 959.66 Mn |
| 10 | Lyra Therapeutics | - | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 3.27 Mn |
| Sep 30, 2025 | 3.06 Mn |
| Jun 30, 2025 | 3.49 Mn |
| Mar 31, 2025 | 2.25 Mn |
| Dec 31, 2024 | 4.35 Mn |
| Sep 30, 2024 | 4.86 Mn |
| Jun 30, 2024 | 6.10 Mn |
| Mar 31, 2024 | 10.06 Mn |
| Dec 31, 2023 | 9.37 Mn |
| Sep 30, 2023 | 11.05 Mn |
| Jun 30, 2023 | 6.74 Mn |
| Mar 31, 2023 | 6.79 Mn |
| Dec 31, 2022 | 9.03 Mn |
| Sep 30, 2022 | 7.32 Mn |
| Jun 30, 2022 | 2.09 Mn |
| Mar 31, 2022 | 4.24 Mn |
| Dec 31, 2021 | 2.43 Mn |
| Sep 30, 2021 | 2.24 Mn |
| Jun 30, 2021 | 1.81 Mn |
| Mar 31, 2021 | 1.99 Mn |
| Dec 31, 2020 | 1.89 Mn |
| Sep 30, 2020 | 1.59 Mn |
| Jun 30, 2020 | 1.85 Mn |
| Mar 31, 2020 | 1.02 Mn |
| Dec 31, 2019 | 3.24 Mn |